{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.464.1003.196.12.1202","meta":{"versionId":"13","lastUpdated":"2017-05-04T01:00:13.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"NCQA PHEMUR Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2017-05-04"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1202","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.464.1003.196.12.1202"}],"version":"20170504","name":"DapsoneAndPyrimethamine","title":"Dapsone and pyrimethamine","status":"active","experimental":false,"date":"2017-05-04T01:00:13-04:00","publisher":"NCQA PHEMUR","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development)","compose":{"include":[{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1202"]}]},"expansion":{"identifier":"urn:uuid:5a5ca9ca-2fd8-4f12-ae33-35b875972d5d","timestamp":"2023-12-11T02:34:19-05:00","total":1,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"105337","display":"dapsone 100 MG / pyrimethamine 12.5 MG Oral Tablet"}]}}